Garrido-Laguna, Ignacio <br/><br/>
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.  [electronic resource] 

 -  PloS one  2012 
 - e38033 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0038033  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Class I Phosphatidylinositol 3-Kinases<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Humans<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Middle Aged<br/>Mutation<br/>Mutation Rate<br/>Neoplasm Metastasis<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins p21(ras)<br/>Signal Transduction--drug effects<br/>TOR Serine-Threonine Kinases--metabolism<br/>Treatment Outcome<br/>ras Proteins--genetics